江苏吴中董事长被立案，退市危机加剧

Core Viewpoint - Jiangsu Wuzhong has faced multiple negative events since 2025, including regulatory scrutiny and financial difficulties, leading to its stock being placed on risk warning status and potential delisting [1][3][5]. Group 1: Regulatory Issues - The chairman of Jiangsu Wuzhong, Qian Qunshan, received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation for suspected violations of information disclosure laws [1]. - The company has been under investigation since February 27, 2025, for similar allegations, with the CSRC deciding to initiate a case against it [3]. - A subsidiary's former legal representative was prosecuted for involvement in fraudulent activities related to export tax rebates [3]. Group 2: Financial Performance - In 2024, Jiangsu Wuzhong reported a revenue of 1.599 billion yuan, a year-on-year decrease of 28.64%, but achieved a net profit of 70.48 million yuan, marking a turnaround from losses [4]. - The pharmaceutical segment generated revenue of 1.229 billion yuan, down 33.19% year-on-year, while the medical beauty sector saw a significant increase in revenue to 330 million yuan, up 4225.65% [4]. Group 3: Corporate Governance and Internal Control - Despite a slight improvement in financial performance, Jiangsu Wuzhong has revealed serious internal control issues, pushing the company closer to delisting [5]. - The controlling shareholder, Suzhou Wuzhong Investment Holdings, held a 17.24% stake in the company as of the first quarter of 2025 [6].